Lure, France

Marc Schneider


 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2010-2011

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Marc Schneider

Introduction

Marc Schneider is a notable inventor based in Lure, France. With a significant contribution to the field of antibacterial compounds, he holds two patented inventions that reflect his expertise and innovative approach in the pharmaceutical domain.

Latest Patents

Marc Schneider's latest patents include groundbreaking advancements in antibacterial agents. The first patent is for "9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials", which introduces a series of compounds with the potential for effective antibacterial properties. The second patent is titled "7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials", also focusing on a new class of compounds designed to combat bacterial infections.

Career Highlights

Currently, Marc Schneider works with Vetoquinol S.A., a well-respected company in the veterinary pharmaceutical industry. His role at the company has allowed him to further develop his scientific research and apply his findings to the creation of new antibacterial products. His commitment to research has established him as a valuable asset in his field.

Collaborations

Throughout his career, Marc has collaborated with other notable researchers such as Paola Ciapetti and Florence Chery-Mozziconacci. These collaborations have fostered an environment of shared knowledge and innovation, contributing to the successful development of antibacterial compounds.

Conclusion

Marc Schneider is a prominent inventor whose research and innovations in antibacterial agents have significant implications for both human and veterinary medicine. His contributions through his patents underscore the importance of continued innovation in the fight against bacterial infections, making him a key figure in contemporary pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…